Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE study of adherence after switching to Rebif New Formulation with RebiSmart in relapsing multiple sclerosis
2009-013333-24Phase 4Completed
- Sponsor
- Merck Serono
- Start
- Jul 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Merck Serono. Primary endpoint: Proportion of subjects with at least 80% of completed injections at Week 12. Started Jul 2009; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-013333-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013333-24.